The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.

Abstract

BACKGROUND:

Omalizumab is an effective and well-tolerated treatment for chronic spontaneous urticaria (CSU). Markers and predictors of response are largely unknown, but needed to optimize omalizumab treatment. Omalizumab targets IgE, and IgE levels may be linked to the effects of treatment. We evaluated whether response rates to treatment with omalizumab in patients with CSU are linked to their baseline IgE levels, their IgE levels after omalizumab treatment, and the ratio of on treatment IgE and baseline IgE levels.

METHODS:

Chronic spontaneous urticaria (CSU) patients (n = 113) were treated with omalizumab 300 mg/4 weeks for 12 weeks, when their treatment responses, that is, no, partial, or complete response, were assessed by use of the urticaria activity score, physician and patient visual analog scale, and treatment effectiveness score. Total IgE levels were measured before treatment (bIgE) with omalizumab and 4 weeks thereafter (w4IgE).

RESULTS:

Nonresponders to omalizumab had significantly lower bIgE levels (17.9, 17.0-55.0 IU/mL) than partial responders (82.0, 46.2-126.5 IU/mL, P = .008) and complete responders (73.7, 19.45-153.8 IU/mL, P = .032). Nonresponders also had lower w4IgE levels and lower ratios of w4IgE/bIgE levels than partial and complete responders (P < .001). Nonresponse to omalizumab was best predicted by patients' w4IgE/bIgE ratios, significantly better than by bIgE levels (P = .016).

CONCLUSIONS:

In CSU, total IgE levels and their change predict the response to treatment with omalizumab. The assessment of pre- and post-treatment IgE levels and their ratio may help to improve the management of CSU in patients who require omalizumab treatment.

• Authors: R Ertas, K Ozyurt, M Atasoy, T Hawro, M Maurer
• Journal: Allergy (Allergy) Vol. 73 Issue 3 Pg. 705-712 (03 2018) ISSN: 1398-9995 [Electronic] Denmark
• PMID: 29083482 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Chemical References

• Anti-Allergic Agents
• Omalizumab
• Immunoglobulin E

Topics

• Adult
• Anti-Allergic Agents (therapeutic use)
• Female
• Humans
• Immunoglobulin E (blood, immunology)
• Male
• Middle Aged
• Omalizumab (therapeutic use)
• Prospective Studies
• Treatment Outcome
• Urticaria (blood, drug therapy, immunology)